ARTICLE | Clinical News
Bladder cancer data gives Tecentriq another first-line win
August 5, 2019 10:35 PM UTC
With more positive data in first-line bladder cancer, Roche's Tecentriq could become the leading immunotherapy agent for the indication.
An interim analysis of the 1,213-patient Phase III IMvigor-130 trial showed Tecentriq atezolizumab plus chemotherapy met the co-primary endpoint of an improvement in progression-free survival (PFS) vs. chemotherapy alone. Roche (SIX:ROG; OTCQX:RHHBY) said data for overall survival, the other co-primary endpoint, aren’t mature yet. ...
BCIQ Company Profiles